反应详情

Following the procedure for 1-((1H-imidazol-2-yl)methyl)-6-(4-(1-aminocyclobutyl)phenyl)-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one, tert-butyl(1-(4-(2-oxo-7-phenyl-1,2,3,4-tetrahydropyrido[3,2-d]pyrimidin-6-yl)phenyl)cyclobutyl)carbamate (12 mg, 0.03 mmol) was reacted to afford the title compound (12 mg, 97%). LCMS (Method D): RT=0.684 min, M+1=371. 1H NMR (500 MHz, MeOD): 7.42-7.38 (4H, m), 7.31-7.28 (3H, m), 7.23 (1H, s), 7.21-7.18 (2H, m), 4.66 (2H, s), 2.81-2.75 (2H, m), 2.63-2.57 (2H, m), 2.26-2.24 (1H, m), 1.99-1.97 (1H, m).

1. customwas reacted